Pharmacoeconomics

Papers
(The TQCC of Pharmacoeconomics is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Authors’ Reply to Comment on “Risk-Adjusted Performance Measures”131
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling117
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?72
Correction to: Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment67
Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment61
Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting57
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children54
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment51
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment44
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy39
The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis39
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy37
The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned37
Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review36
Advancing Methods to Measure and Reward Healthcare Innovation36
Bayesian Meta-Analysis: A Practical Introduction35
Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review34
Innovation Headroom for a Highly Accurate PD-L1 Companion Diagnostic in Non-small Cell Lung Cancer34
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation31
Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling31
Economic Burden Associated with Pulmonary Arterial Hypertension in the United States31
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based 31
The Economic Burden of Inflammatory Arthritis: A Systematic Review30
Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies29
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review29
Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA28
EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions28
Caring for and Caring about in Economic Evaluation: Modelling the Family and Caregiving Effects27
A Framework for Reliable, Transparent, and Reproducible Population-Adjusted Indirect Comparisons26
Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective25
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition25
The Difference Method Approach for Sampling Order Constrained Parameters: An Improved Implementation and Important Limitations24
Time to Close the Gap Between Guidelines and the Reimbursement Policy for Diabetes Treatment in Turkey24
An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada24
A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 Diabetes24
Market Transparency in Medicine Pricing: Pathways to Fair Pricing23
Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review23
The Use of Real-World Data for Estimating Relative Treatment Effects in NICE Health Technology Assessment Submissions: A Review23
Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD)22
Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review22
A Systematic Review of Methods for Estimating Productivity Losses due to Illness or Caregiving in Low- and Middle-Income Countries22
Economic Evaluations of Treatments for Duchenne Muscular Dystrophy: The Caregiver QALY Trap22
Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know22
Measuring the Direct Medical Costs of Hospital-Onset Infections Using an Analogy Costing Framework21
Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models20
Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs20
Drug Pricing Stewardship from Mark Cuban’s Cost Plus Generic Drug Program20
Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia19
A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)19
Quality Appraisal in Systematic Literature Reviews of Studies Eliciting Health State Utility Values: Conceptual Considerations19
Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds18
Economic and Humanistic Burden of Osteoarthritis: An Updated Systematic Review of Large Sample Studies18
Value of Information for Clinical Trial Design: The Importance of Considering All Relevant Comparators18
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry18
Prognostic Testing for Prostate Cancer—A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice17
Acknowledgement to Referees16
Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia16
Comparison of EQ-5D-Y-3L Utility Scores Using Nine Country-Specific Value Sets in Chinese Adolescents16
A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates16
Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor Analysis15
Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated15
Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria15
Application of Multi-level Network Meta-Regression in the NICE Technology Appraisal of Quizartinib for Induction, Consolidation and Maintenance Treatment of Newly Diagnosed FLT3-ITD-Positive Acute Mye15
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China14
Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures14
A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models14
Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer13
Measuring the Indirect Cost of Illness Using EQ-5D-5L While Accounting for Job Characteristics13
Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC)13
Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis13
Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection13
Modelling the Cost-Effectiveness of Diagnostic Tests13
Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”12
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA12
Economic Implications of Endometriosis: A Review12
Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments12
Uncertainty in Matching-Adjusted Indirect Comparisons Using Real-World Evidence: Evidence Assessment Group Perspective12
The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer’s Disease in Sweden12
Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom12
Health Care Resource Utilization and Costs Associated with US Medicaid Sobriety Restrictions on Direct-Acting Antivirals for Hepatitis C Virus: A Retrospective Claims Database Analysis12
Cost-Effectiveness of Thrombopoietin Mimetics in Patients with Thrombocytopenia: A Systematic Review12
A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework12
The Costs of Dementia in Europe: An Updated Review and Meta-analysis12
Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability12
Childhood Transitions Between Weight Status Categories: Evidence from the UK Millennium Cohort Study11
Carers’ Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations11
Societal Versus Healthcare Perspectives on the Cost Effectiveness of Ocrelizumab for Treatment of Primary Progressive Multiple Sclerosis in Aotearoa New Zealand11
Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?11
Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments11
Systematic Review of the Relative Social Value of Child and Adult Health11
Considerations Around the Inclusion of Children and Young People’s Time in Economic Evaluation: Findings from an International Delphi Study11
Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review11
How do Health State Values Differ When Respondents Consider Adults Versus Children Living in Those States? A Systematic Review11
Examining the Effect of Depicting a Patient Affected by a Negative Reimbursement Decision in Healthcare on Public Disagreement with the Decision11
Economic Evaluation of Interventions to Reduce Antimicrobial Resistance: A Systematic Literature Review of Methods11
Content Comparison of Quality-of-Life Instruments Used in Economic Evaluations of Sleep Disorder Interventions: A Systematic Review10
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan10
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer10
Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation10
Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias10
Informal Caregiving Provision for Disabled or Elderly in the Families and Work Productivity: Evidence from 11 Waves of an Australian Population-Based Cohort10
Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer10
Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges10
A Value Set for the EQ-5D-Y-3L in the Netherlands10
HTA Barriers for Conditional Approval Drugs9
Informal Care Costs According to Age and Proximity to Death to Support Cost-Effectiveness Analyses9
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK9
Incorporating Complexity and System Dynamics into Economic Modelling for Mental Health Policy and Planning9
Correction: Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis9
Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meni9
Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L9
A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process9
Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time9
Conceptual Framework for Optimised Proxy Value Set Selection Through Supra-National Value Set Development for the EQ-5D Instruments9
Using AI in the Economic Evaluation of AI-Based Health Technologies9
Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study9
0.12169003486633